Evaluation of the new anti-inflammatory compound ethyl salicylate 2-O-β-d-glucoside and its possible mechanism of action

International Immunopharmacology

Volumn 15, Issue 2, 2013, Pages 303-308

  Xin, Wenyu ^a   Huang, Chao ^a   Zhang, Xue ^a   Zhang, Guidong ^b   Ma, Xiaowei ^a   Sun, Lan ^a   Wang, Chao ^a   Zhang, Dongming ^a   Zhang, Tiantai ^a   Du, Guanhua ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b HEBEI UNITED UNIVERSITY   (China)

Author keywords

Cyclooxygenase 1; Cyclooxygenase 2; Ethyl Salicylate 2 O d Glucoside; Inflammation; iNOS; NF B

Indexed keywords

ANTIINFLAMMATORY AGENT; ETHYL SALICYLATE 2 O BETA DEXTRO GLUCOSIDE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; NITRIC OXIDE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG MECHANISM; ENZYME INHIBITION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; CELL NUCLEUS; ENZYME REPRESSION; GAULTHERIA; GLUCOSIDES; MACROPHAGES; MICE; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SALICYLATES; SIGNAL TRANSDUCTION;

EID: 84872896161     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2012.11.014     Document Type: Article

References (46)

1. M. Chignard, and V. Balloy Neutrophil recruitment and increased permeability during acute lung injury induced by lipopolysaccharide Am J Physiol Lung Cell Mol Physiol 279 2000 L1083 L1090
2. R. Nieminen, R. Korhonen, T. Moilanen, A.R. Clark, and E. Moilanen Aurothiomalate inhibits cyclooxygenase 2, matrix metalloproteinase 3, and interleukin-6 expression in chondrocytes by increasing MAPK phosphatase 1 expression and decreasing p38 phosphorylation: MAPK phosphatase 1 as a novel target for antirheumatic drugs Arthritis Rheum 62 2010 1650 1659
3. A. Sica, P. Allavena, and A. Mantovani Cancer related inflammation: the macrophage connection Cancer Lett 267 2008 204 215
4. R.M. Wright, L.A. Ginger, N. Kosila, N.D. Elkins, B. Essary, and J.L. McManaman Mononuclear phagocyte xanthine oxidoreductase contributes to cytokine-induced acute lung injury Am J Respir Cell Mol Biol 30 2004 479 490
5. E. Szliszka, D. Skaba, Z.P. Czuba, and W. Krol Inhibition of inflammatory mediators by neobavaisoflavone in activated RAW264.7 macrophages Molecules 16 2011 3701 3712
6. S.J. Kim, M.C. Kim, B.J. Lee, D.H. Park, S.H. Hong, and J.Y. Um Anti-inflammatory activity of chrysophanol through the suppression of NF-kappaB/caspase-1 activation in vitro and in vivo Molecules 15 2010 6436 6451
7. D. Zhang, R. Liu, L. Sun, C. Huang, C. Wang, and D.M. Zhang Anti-inflammatory activity of methyl salicylate glycosides isolated from Gaultheria yunnanensis (Franch.) Rehder Molecules 16 2011 3875 3884
8. C.R. Raetz, and C. Whitfield Lipopolysaccharide endotoxins Annu Rev Biochem 71 2002 635 700
9. A.L. Weaver Efficacy and safety of the anti-TNF biologic agents Mod Rheumatol 14 2004 101 112
10. A.M. Hung, C.D. Ellis, A. Shintani, C. Booker, and T.A. Ikizler IL-1beta receptor antagonist reduces inflammation in hemodialysis patients J Am Soc Nephrol 22 2011 437 442
11. J.B. Kim, A.R. Han, E.Y. Park, J.Y. Kim, W. Cho, and J. Lee Inhibition of LPS-induced iNOS, COX-2 and cytokines expression by poncirin through the NF-kappaB inactivation in RAW 264.7 macrophage cells Biol Pharm Bull 30 2007 2345 2351
12. C.S. Lai, Y.S. Lai, D.H. Kuo, C.H. Wu, C.T. Ho, and M.H. Pan Magnolol potently suppressed lipopolysaccharide-induced iNOS and COX-2 expression via downregulating MAPK and NF-κB signaling pathways J Funct Foods 3 2011 198 206
13. C.D. Funk Prostaglandins and leukotrienes: advances in eicosanoid biology Science 294 2001 1871 1875
14. H.S. Jeong, J.H. Kim, H.Y. Choi, E.R. Lee, and S.G. Cho Induction of cell growth arrest and apoptotic cell death in human breast cancer MCF-7 cells by the COX-1 inhibitor FR122047 Oncol Rep 24 2010 351 356
15. N. Suh, T. Honda, H.J. Finlay, A. Barchowsky, C. Williams, and N.E. Benoit Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages Cancer Res 58 1998 717 723
16. S. Maeda, and M. Omata Inflammation and cancer: role of nuclear factor-kappaB activation Cancer Sci 99 2008 836 842
17. G. Sethi, and V. Tergaonkar Potential pharmacological control of the NF-kappaB pathway Trends Pharmacol Sci 30 2009 313 321
18. N.D. Perkins Integrating cell-signalling pathways with NF-kappaB and IKK function Nat Rev Mol Cell Biol 8 2007 49 62
19. S. Shishodia, S. Majumdar, S. Banerjee, and B.B. Aggarwal Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1 Cancer Res 63 2003 4375 4383
20. M.J. Wu, L. Wang, H.Y. Ding, C.Y. Weng, and J.H. Yen Glossogyne tenuifolia acts to inhibit inflammatory mediator production in a macrophage cell line by downregulating LPS-induced NF-kappa B J Biomed Sci 11 2004 186 199
21. X.J. Ma, J.H. Zheng, and X.Z. Chen Studies on resources of ethnomedicine Gaultheria leucocarpa var. yunnanensis Zhongguo Zhong Yao Za Zhi 26 2001 85 89
22. X. Lan, R. Liu, L. Sun, T. Zhang, and G. Du Methyl salicylate 2-O-beta-d-lactoside, a novel salicylic acid analogue, acts as an anti-inflammatory agent on microglia and astrocytes J Neuroinflammation 8 2011 98
23. T. Zhang, L. Sun, R. Liu, D. Zhang, X. Lan, and C. Huang A novel naturally occurring salicylic acid analogue acts as an anti-inflammatory agent by inhibiting nuclear factor-kappaB activity in RAW264.7 macrophages Mol Pharm 9 2012 671 677
24. B. Zhang, X.L. He, Y. Ding, and G.H. Du Gaultherin, a natural salicylate derivative from Gaultheria yunnanensis: towards a better non-steroidal anti-inflammatory drug Eur J Pharmacol 530 2006 166 171
25. D. Dess, H.P. Kleine, D.V. Weinberg, R.J. Kaufman, and R.S. Sidhu Phase-transfer catalyzed synthesis of acetylated aryl beta-d-glucopyranosides and aryl beta-d-galactopyranosides Synthesis 1981 883 885
26. W. Li, H. Liu, and Q. You Synthesis of 4-aminophenlo-glucopyranoside J China Pharm Univ 35 2004 397 400
27. B.N. Mbadugha, and F.M. Menger Sugar/steroid/sugar conjugates: sensitivity of lipid binding to sugar structure Org Lett 5 2003 4041 4044
28. S. Xu, X. Ling, H. Liu, and C. Wang Study on synthesis of glycosyl esters of vanillic acid Chem Res Appl 18 2006 870 874
29. S.N. Lam, and J. Gervay-Hague Efficient synthesis of Man2, Man3, and Man5 oligosaccharides, using mannosyl iodide donors J Org Chem 70 2005 8772 8779
30. E. Szliszka, Z.P. Czuba, M. Domino, B. Mazur, G. Zydowicz, and W. Krol Ethanolic extract of propolis (EEP) enhances the apoptosis- inducing potential of TRAIL in cancer cells Molecules 14 2009 738 754
31. E. Szliszka, Z.P. Czuba, K. Jernas, and W. Krol Dietary flavonoids sensitize HeLa cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) Int J Mol Sci 9 2008 56 64
32. L.C. Green, D.A. Wagner, J. Glogowski, P.L. Skipper, J.S. Wishnok, and S.R. Tannenbaum Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids Anal Biochem 126 1982 131 138
33. Y.R. Mahida The key role of macrophages in the immunopathogenesis of inflammatory bowel disease Inflamm Bowel Dis 6 2000 21 33
34. W. Krol, Z.P. Czuba, M.D. Threadgill, B.D. Cunningham, and G. Pietsz Inhibition of nitric oxide (NO.) production in murine macrophages by flavones Biochem Pharmacol 50 1995 1031 1035
35. P.C. Kuo, and R.A. Schroeder The emerging multifaceted roles of nitric oxide Ann Surg 221 1995 220 235
36. M.J. Miller, and M.B. Grisham Nitric oxide as a mediator of inflammation? - you had better believe it Mediators Inflamm 4 1995 387 396
37. Y.W. Su, W.F. Chiou, S.H. Chao, M.H. Lee, C.C. Chen, and Y.C. Tsai Ligustilide prevents LPS-induced iNOS expression in RAW 264.7 macrophages by preventing ROS production and down-regulating the MAPK, NF-kappaB and AP-1 signaling pathways Int Immunopharmacol 11 2011 1166 1172
38. B.H. Kim, K.S. Kang, and Y.S. Lee Effect of retinoids on LPS-induced COX-2 expression and COX-2 associated PGE(2) release from mouse peritoneal macrophages and TNF-alpha release from rat peripheral blood mononuclear cells Toxicol Lett 150 2004 191 201
39. J. Roca-Ferrer, F.J. Garcia-Garcia, J. Pereda, M. Perez-Gonzalez, L. Pujols, and I. Alobid Reduced expression of COXs and production of prostaglandin E(2) in patients with nasal polyps with or without aspirin-intolerant asthma J Allergy Clin Immunol 128 2011 66 72 [e1]
40. P. Ferrera, and C. Arias Differential effects of COX inhibitors against beta-amyloid-induced neurotoxicity in human neuroblastoma cells Neurochem Int 47 2005 589 596
41. R. Calvello, M.A. Panaro, M.L. Carbone, A. Cianciulli, M.G. Perrone, and P. Vitale Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells Pharmacol Res 65 2012 137 148
42. P.A. Baeuerle, and D. Baltimore NF-kappa B: ten years after Cell 87 1996 13 20
43. Y.C. Oh, W.K. Cho, G.Y. Im, Y.H. Jeong, Y.H. Hwang, and C. Liang Anti-inflammatory effect of Lycium Fruit water extract in lipopolysaccharide- stimulated RAW 264.7 macrophage cells Int Immunopharmacol 13 2012 181 189
44. M.S. Kim, and S.H. Kim Inhibitory effect of astragalin on expression of lipopolysaccharide-induced inflammatory mediators through NF-kappaB in macrophages Arch Pharm Res 34 2011 2101 2107
45. H. Sakurai, H. Chiba, H. Miyoshi, T. Sugita, and W. Toriumi IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain J Biol Chem 274 1999 30353 30356
46. K. Brown, S. Park, T. Kanno, G. Franzoso, and U. Siebenlist Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha Proc Natl Acad Sci U S A 90 1993 2532 2536